Dren Bio
Dren Bio is a clinical-stage biopharmaceutical company developing first-in-class antibody therapeutics that selectively deplete pathogenic cells for cancer, autoimmune, and other serious diseases. Its lead candidate, dibotatug, targets CD94 to deplete pathogenic cytotoxic cells and is in late-stage trials for rare blood cancers including cytotoxic T-cell lymphoma and large granular lymphocytic leukemia. The company's proprietary Targeted Myeloid Engager and Phagocytosis Platform generates bispecific antibodies designed to engage a novel phagocytic receptor on myeloid cells for controlled cell depletion.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Raised to date
$505MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 4 rounds
+12$350M · Undisclosed
Announced Oct 2026 · from article date
Disclosed cumulative: $480M
Founders
Product
Problem
Current treatments for cancer and serious autoimmune diseases often lack specificity, leading to off-target effects and limited efficacy, while many pathogenic cell types remain untargeted by existing therapies. Patients with rare blood cancers such as cytotoxic T-cell lymphoma and large granular lymphocytic leukemia face particularly poor prognoses with no approved therapies available.
Solution
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics that selectively deplete disease-causing cells. Leveraging its proprietary Targeted Myeloid Engager and Phagocytosis Platform, the company creates first-in-class agents that engage immune effector mechanisms to eliminate pathogenic cells with high precision. Its lead program, dibotatug, is a first-in-class, fully human monoclonal antibody targeting CD94 that selectively depletes pathogenic cytotoxic cells while preserving the broader immune system. The platform uses bispecific antibodies engineered to enable controlled myeloid cell activation only in the presence of the target antigen, potentially offering greater therapeutic indexes and superior safety profiles compared to T-cell engagers and antibody-drug conjugates. Dren Bio's pipeline includes two clinical programs in oncology and autoimmune indications, supported by additional preclinical candidates across oncology, immunology, and neurology.
Target Audience
Primary customers are pharmaceutical partners, oncology and immunology researchers, and clinicians seeking highly selective antibody therapies for cancer, autoimmune diseases, and other serious conditions with significant unmet medical need.
Features
- Proprietary Targeted Myeloid Engager technology that induces potent depletion of pathogenic cells, protein aggregates, and other disease-causing agents by engaging a novel phagocytic receptor selectively expressed on myeloid cells
- Bispecific antibodies engineered for controlled myeloid cell activation only in the presence of the target antigen, potentially enabling greater therapeutic indexes and superior safety profiles compared to T-cell engagers and ADCs
- Lead candidate dibotatug (DR-01), a first-in-class CD94-targeting monoclonal antibody that selectively depletes pathogenic cytotoxic cells while preserving the broader immune system
- Clinical data from more than 300 patients dosed in Ph1/2 studies demonstrating high overall and complete response rates in relapsed/refractory cytotoxic T-cell lymphoma and large granular lymphocytic leukemia with a favorable safety and tolerability profile
- Broad pipeline spanning oncology, immunology, and neurology, with platform candidate DR-0202 currently being evaluated for solid tumors
- Clinical-stage development approach with emphasis on safety, selectivity, and mechanistic validation